Current Research Studies

An Interventional, Efficacy, And Safety, Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With An Open-Label Extension To Investigate Rimegepant In Migraine Prevention In Adolescents Greater Than Or Equal To 12 And Less Than 18 Years Of Age With Chronic Migraine

Rimegepant Chronic Migraine

Phase: III
Clinicaltrials.gov ID: NCT06616194

What is the goal of the study?

This is a global, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of rimegepant in migraine prevention in adolescents ≥ 12 to < 18 years of age with chronic migraine. All participants are to be administered 75 mg (1 x 75 mg ODT) rimegepant or matching placebo.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Heidi Blume
Study Team Member: Jacqueline Lee-Eng, [email protected]